Tg Therapeutics (TGTX) Enterprise Value (2011 - 2026)

Tg Therapeutics' Enterprise Value history runs 16 years deep, the most recent figure standing at -$75.1 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 72.82% year-over-year to -$75.1 million in Q1 2026; TTM through Mar 2026 was -$75.1 million, a 72.82% increase from a year earlier, with the FY2025 full-year figure at -$64.1 million, up 51.21% from the prior year.
• Enterprise Value declined to -$75.1 million in Q1 2026 per TGTX's latest filing, from -$64.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$64.1 million in Q4 2025 and bottomed at -$341.0 million in Q3 2024.
• The 5-year median for Enterprise Value is -$209.8 million (2024), against an average of -$194.1 million.
• Across the five-year window, Enterprise Value sank 50.16% in 2024 and jumped 72.82% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$161.7 million in 2022, then tumbled by 34.53% to -$217.5 million in 2023, then surged by 39.55% to -$131.5 million in 2024, then jumped by 51.21% to -$64.1 million in 2025, then dropped by 17.05% to -$75.1 million in 2026.
• Per Business Quant, the three latest TGTX Enterprise Value figures stand at -$75.1 million (Q1 2026), -$64.1 million (Q4 2025), and -$235.8 million (Q3 2025).